Preliminary In Vitro Effects of CD8+ T Lymphocyte Specific for the CD20 Alternative Splicing D393-CD20 Peptide Expressed on Burkitt Lymphoma Cells.

Hamid Chegni,Zuhair M Hassan,Farzaneh Sabouni,Marzieh Ebrahimi,Roberto Nisini

doi:10.31557/apjcp.2019.20.8.2563

Abstract

The effective discovery of clinically relevant tumor antigens holds a fundamental role for the development of new diagnostic tools and anticancer immunotherapies. D393-CD20 mRNA is absent from normal resting B cells but present in various malignant or transformed B cells. CD8+T lymphocytes play a central role in immunity to cancer. In this study, we want use from T CD8+ against D393-CD20 for effect in RAMOS cell line. After isolation and expanding of specific TCD8 + Lymphocyte against D393-CD20 antigen, for examining the effect of specialized T lymphocyte clone of D393-CD20 antigen on RAMOS cell line, we co-cultured them together, and the rate of apoptosis were examined by flow cytometry and cytotoxicity techniques by using MTT technique. We observed that specialized TCD8+ lymphocyte of D393-CD20 antigen can induce apoptosis in malignant B-lymphocytes, and this antigen can be a proper target for immunotherapy.

Highlights

CD8+T lymphocytes play a central role in immunity to cancer through their capacity to kill malignant cells upon recognition by T-cell receptor (TCR) of specific antigenic peptides presented on the surface of target cells by human leukocyte antigen class I (HLA-I)/beta-2-microglobulin (β2m) complexes (Bossi et al, 2002)
After staining some of the selected T lymphocyte clone cells of D393-CD20 antigen with Anti CD4 connected to FITC stain and Anti CD8 connected to PE, by using flow cytometry device, it was determined that 86.6% of selected cell populations were CD8+ and CD4
Results of MTT test related to RAMOS cell line co-cultured with specialized T lymphocytes of D393-CD20 antigen

Summary

Introduction

CD8+T lymphocytes play a central role in immunity to cancer through their capacity to kill malignant cells upon recognition by T-cell receptor (TCR) of specific antigenic peptides presented on the surface of target cells by human leukocyte antigen class I (HLA-I)/beta-2-microglobulin (β2m) complexes (Bossi et al, 2002). Evidence for antitumor CD8+T-cell immunity was provided by isolation of tumor-specific CTL from peripheral blood or tumor tissue of patients with diverse cancers, such as melanoma and lung carcinoma (Boon et al.,1997; Echchakir et al, 2000; Karanikas, 2001; Slingluff et al.,1994; Weynants et al, 1999). Aside from its role in physiological cell adaptation, alternative splicing has been shown to occur in human diseases, including cancer (Kaida et al, 2012). Cancer-specific splice variants are of significant interest as they may be involved in pathogenesis and may further potentially be used as biomarkers and generate novel targets for therapy

Methods

Results

Conclusion